Accenture’s Chuck Rozea on Boston’s unique position to help cut the cost of new treatments


Scientists continue to make incredible breakthroughs in biopharmaceutical research. The FDA approved 55 new drugs last year, and promising new therapies for cancer, Alzheimer’s, diabetes and a host of other diseases are on the horizon.

But one big hurdle stands in the way of transforming lives: Cost.

About half of U.S. adults in the most recent Kaiser Family Foundation health care poll say they have difficulty affording health care, with about a quarter skipping or not taking their medicines…

Previous Waltham biotech brings in $118M for immunotherapy
Next Novavax says its Omicron-specific vaccine candidate works as a booster